替比夫定优化方案与恩替卡韦治疗HBeAg阳性慢性乙型肝炎的药物经济学评价

发布时间：2018-03-04 11:28

本文选题：肝炎　切入点：乙型　出处：《实用医学杂志》2015年07期 　论文类型：期刊论文

【摘要】：目的:对替比夫定优化方案与恩替卡韦方案治疗HBe Ag阳性慢性乙型肝炎进行药物经济学评价。方法:根据慢性乙型肝炎进展规律,构建含多个健康状态的Markov模型,以替比夫定单药方案作基准,估计替比夫定优化方案与恩替卡韦方案治疗HBe Ag阳性慢性乙型肝炎患者的长期效果和医疗费用,并进行增量分析。结果:使用恩替卡韦方案使HBe Ag阳性慢性乙型肝炎患者获得35.95年的期望生存年和22.94个质量调整生命年,其总费用为349 279.27元,每延长1个质量调整生命年多需的医疗费用为15 225.77元。使用替比夫定优化方案获得了长于恩替卡韦方案的36.11年的期望生存年和23.08个质量调整生命年,其总费用为348 863.62元,每延长1个质量调整生命年多需的医疗费用为15 115.41元,低于恩替卡韦方案的15 225.77元。结论:使用替比夫定优化方案相比恩替卡韦方案具有略优的成本效果,可以作为临床上HBe Ag阳性慢性乙型肝炎抗病毒治疗的较优选择。
[Abstract]:Objective: to optimize the scheme and grace of telbivudine pharmacoeconomic evaluation of entecavir treatment of HBe positive chronic hepatitis B Ag. Methods: according to the law of the development of chronic hepatitis B, to construct the Markov model with multiple health status, in order to make reference for biff regimen, estimate the long-term effect of telbivudine and entecavir optimization program for the treatment of patients with HBe Ag positive chronic hepatitis B patients and medical costs, and incremental analysis. Results: the use of entecavir solution will enable HBe Ag positive chronic hepatitis B patients was 35.95 years and 22.94 years expected survival quality adjusted life years, the total cost of 349279.27 yuan, 1 per quality adjusted life year required the medical cost was 15225.77 yuan. The use of telbivudine optimization scheme received entecavir for longer than 36.11 years and 23.08 years expected survival quality adjusted life years, The total cost of 348863.62 yuan, 1 per quality adjusted life year for medical expenses is 15115.41 yuan, 15225.77 yuan lower than that of entecavir scheme. Conclusion: the use of telbivudine compared entecavir optimization scheme has superior cost, can be used as a better choice of clinical HBe Ag positive chronic hepatitis virus the treatment of hepatitis.

【作者单位】：广州医科大学附属第二医院感染科;
【基金】：中国肝炎防治基金会慢性乙肝科研基金项目(编号:GHF2012208)
【分类号】：R512.62

【共引文献】